

PRODUCT INFORMATION



MEN10207 (acetate)

Item No. 43055

Formal Name: L- α -aspartyl-L-tyrosyl-D-tryptophyl-L-valyl-D-tryptophyl-D-tryptophyl-L-argininamide, acetate

Synonyms: Asp-Tyr-D-Trp-Val-D-Trp-D-Trp-Arg-NH₂, [Tyr⁵,D-Trp^{6,8,9},Arg¹⁰]-Neurokinin A (4-10), [Tyr⁵,D-Trp^{6,8,9},Arg¹⁰]-NKA (4-10)

Peptide Sequence: DYwVwwR-NH₂

MF: C₅₇H₆₈N₁₄O₁₀ • XC₂H₄O₂


FW: 1,109.3

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MEN10207 (acetate) is supplied as a solid. A stock solution may be made by dissolving the MEN10207 (acetate) in the solvent of choice, which should be purged with an inert gas. MEN10207 (acetate) is soluble (≥10 mg/ml) in DMSO. MEN10207 (acetate) is slightly soluble (0.1-1 mg/ml) in ethanol.

Description

MEN10207 is a peptide neurokinin-2 (NK₂) receptor antagonist.¹ It inhibits contractions induced by neurokinin A (NKA) in endothelium-deprived isolated rabbit pulmonary artery (pA₂ = 7.89), which is endogenously enriched in NK₂ receptors. It is selective for NK₂ receptors in isolated rabbit pulmonary artery over NK₂ receptors in isolated hamster trachea (pA₂ = 5.9 using NKA as an agonist) and NK₁ receptors in isolated guinea pig ileum (pA₂ = 5.52 using substance P methyl ester as an agonist), tissues that highly express these respective receptors, as well as NK₃ receptors in isolated guinea pig cerebral cortex membranes (K_i = >10 μM). *In vivo*, MEN10207 (1 μmol/kg) inhibits increases in bladder motility induced by the NK₂ receptor agonist [β-Ala⁸]-NKA (4-10) in anesthetized rats, as well as [β-Ala⁸]-NKA (4-10)-induced increases in bronchoconstriction in anesthetized guinea pigs. However, MEN10207 also induces bladder motility in anesthetized rats and bronchoconstriction in anesthetized guinea pigs when administered alone.

Reference

1. Maggi, C.A., Giuliani, S., Ballati, L., *et al.* *In vivo* evidence for tachykinergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376. *J. Pharmacol. Exp. Ther.* **257**(3), 1172-1178 (1991).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/01/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM